Speakers
(Alphabetically)
Prof. Dr. Abdullah Elhusseiny
He was promoted to a
lecturer 2004, assistant professor 2010, a professor 2015, in ophthalmology,
Al-Azhar University.
He is working as a
consultant of Ocular Oncology at National Eye Center, Rod Elfarg and
International Eye Hospital from 2004, till present.
He joined CCHC, 57357 as a
consultant of Ophthalmology and ocular oncology since 2013 till present.
He is currently a Professor
of Ophthalmology, and Head of Oculoplasty and Ocular Oncology Unit, Al-Azhar
University Hospitals since 2015 till present.
of Ophthalmology, and Head of Oculoplasty and Ocular Oncology Unit, Al-Azhar
University Hospitals since 2015 till present.
He is also the head of
Ophthalmology Department, CCHC, 57357 since 2018 till present.
Founder and chairman of board of Eye See Center, Cairo, Egypt.
Prof. Dr. Ahmed Elghoneimy
Ahmed does research in Oncology and Orthopedic Surgery.
Their most recent publication is ‘Limb Salvage for Primary Malignant Bone Tumors of the Distal Leg in Skeletally Immature Patients: Ankle Arthrodesis Using Vascularized Ipsilateral or Contralateral Fibular Flap‘.
Prof. Dr. Alaa Elhaddad
Dr. Elhaddad served as the ex-dean of the National Cancer Institute, Cairo University for four years and he is the Head of the African BMT society at present.
In addition, he is a board member of several regional and international scientific and academic societies.
His main areas of interest include Bone Marrow Transplantation for hematological disorders and targeted therapies for pediatric malignancies.
Prof. Dr. Andria Ferrari
He is founding member and member of the Board of the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) and the
Principal Coordinator of the EpSSG Scientific Committee on Non-rhabdomyosarcoma
soft tissue sarcomas.
He is the coordinator of the Italian AIEOP (Associazione
Italiana di Ematologia e Oncologia Pediatrica) Working Group on Soft Tissue Sarcomas
concerning pediatric rare tumors.
He is the chairman of the European Cooperative Study Group for Pediatric Rare Tumors ExPERT, and co-founder and co-coordinator of the Italian TREP project (Tumori Rari Età Pediatrica – Rare Tumors in Pediatric Age).
Prof. Dr. Annalisa Ruggeri
Dr Ruggeri then completed training in clinical
research statistics and methodology at the Pierre and Marie Curie University,
Paris, France, and in clinical research project coordination at the Paris
Diderot University, Paris, France.
Dr Ruggeri worked as a Junior Physician at the
San Raffaele Hospital, Milan, Italy, between 2006 and 2007. In 2007, Dr Ruggeri
was awarded with the EBMT-AMGEN fellowship which she undertook at the Hôpital
Saint-Louis, Paris, France.
Since 2007, Dr Ruggeri has been working as a
Research Physician at Eurocord where she coordinates research. Dr Ruggeri is
also currently a Hematologist practising at IRCCS Ospedale Pediatrico Bambino
Gesù, Rome, Italy, and undertakes research at the Haematology and Bone Marrow
Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Prof. Dr. Asmaa Hamouda
Prof. Dr. Boro Dropulic
As Chief Executive Officer, Boro brings 30+ years of leadership and experience in the design, development, manufacturing, clinical translation, regulatory, clinical implementation, and commercialization of Lentiviral vector technology. After a Fogarty Fellowship at the NIH, he joined the faculty at JHU where he worked on developing Lentiviral vectors as delivery systems for gene therapy
After 4 years in academia, he founded his first company ViRxSys and led the team that first demonstrated the safety of Lentiviral vectors in humans with his UPenn colleagues. Later he founded Lentigen, which first developed the Lentiviral vector used to produce Kymriah™, the first FDA-approved gene therapy product. He implemented and directed the company’s CDMO business model and therapeutic pipeline of gene therapy products. He led Lentigen until 2021, and then left to co-found and launch Caring Cross, a 501 (c)(3) non-profit, and serves as the Executive Director. Lentiviral vectors are critical to produce many gene therapy products such as CAR-T cells and gene-modified Hematopoietic Stem Cells (HSCs) for the treatment of an increasing number of important diseases. Presently there are huge bottlenecks in obtaining high quality Lentiviral vectors in a reasonable time that motivates investigators and investors alike. This delays and puts at risk the development and commercialization of innovative and potentially curative gene therapies that are desperately needed. Seeing a need to help investigators improve and accelerate their medicinal concepts needing Lentiviral vectors into the clinic, Vector BioMed was launched and Boro serves as the Chief Executive Officer.
Prof. Dr. Cullen Dutmer
He served as Vice President of the Colorado Allergy & Asthma Society from 2017-2019 and took on the position of Chairman in 2020.
Prof. Dr. Dina Hossam
Prof. Dr. Elena Hsieh
The ultimate goal of her research is to identify immune parameters that predict and determine disease flare/relapse and prognosis in individual patients, and to devise immune-modulatory strategies that can decrease flare/relapse rate and prevent end-organ damage.
Prof. Dr. Emad Ebeid
Training course in the Bone Marrow Transplantation Department, St.Jude Children Research Hospital at 2000. Training course in the BMT unit, Royal Marsden, Sutton, London at1999. Surgery Training, Department of Surgery, McMaster University-Hamilton, Ontario, Canada
Prof. Dr. Farouk Hassan
Then he had a Diploma (DIU) of Neurointervention from Paris-Descartes University, France.
He is the Head of the Neurointervention committee, in the national presidential project for waiting lists.
He is the Head of the Interventional Radiology and Neurointervention department, Portsaid, Universal Health Insurance authority.
He is a Member of the Scientific Committee of the Egyptian board of Interventional Radiology, Ministry of health.
Secretary General of the MENA-SINO (Middle East and North African Stroke and Interventional neurotherapy organization)
Member of the WFITN (World Federation of Interventional and Therapeutic Neuroradiology)
Member of the ESMINT (European Society of Minimally invasive Neurological therapy)
Member of WSO (World Stroke Organization)
Prof. Dr. Franziska Wachter
Dr. Wachter has trained in a diverse array of institutions, culminating thus far in her pediatric hematology/oncology fellowship at Boston Children’s Hospital and Dana-Farber Cancer Institute, which has continued to foster her clinical and scientific interests.
She utilizes her unique training in medicine and structural biology to work at the innovative forefront of pediatric oncology and drug development.
Prof. Dr. Gabriela Maron
She is currently the Director of Infectious
Diseases – Bone Marrow Transplant and Cellular Therapy at St. Jude.
Dr. Maron received her MD in her home country of El Salvador, where she also completed pediatrics residency and served as Chief Resident. For her pediatric infectious disease training she joined the University of Tennessee Health Sciences Center – St. Jude Pediatric Infectious Diseases Fellowship program. During this time, she also earned a master’s in clinical epidemiology at the University of Tennessee.
Since joining the St. Jude Faculty in 2013, Dr. Maron has worked predominantly with BMTCT patients. Her goal is to improve outcomes in this population through evidence based clinical care and research.
She is interested in the epidemiology of infections, and determining he best ways to diagnose, prevent and treat infections in children undergoing transplant and cellular therapy.
Prof. Dr. Hesham Eissa
Dr. Eissa is now an Assistant Professor of Pediatrics at Colorado Hospital, USA. His clinical interest is in stem cell transplantation and cellular therapy. More specifically he is interested in stem cell transplantation for non-malignant conditions affecting the blood and immune systems, and late effects of stem cell transplantation.
Prof. Dr. Hisham Abdel-Azim
Prof. Dr. Iman Sidhom
President of Pediatric Oncology East and Mediterranean Group (POEM); and Chairperson of Scientific Medical Advisory Committee (SMAC) at CCHE-57357.Her field of interest is pediatric leukemias and she is the Principal Investigator of Acute Lymphoblastic Leukemia study group at CCHE-57357 and National Cancer Institute,Cairo Univeristy Egypt.
Prof. Dr. Jennifer McArthur
She is the co-founder of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network’s Hematopoietic Stem Cell Transplant (HSCT)/Oncology subgroup and currently sits on the executive committee. Through the PALISI Network and the PBMTC (Pediatric Blood and Marrow Transplant Consortium) she has been involved in multiple clinical research studies. She has been actively involved in IRB work for many years both at the Medical College of Wisconsin and St. Jude. The primary focus of her career has been working towards improving outcomes in critically ill hematology/oncology and cellular therapy patients.
Prof. Dr. Leslie Lehmann
The overall focus of her research is gene therapy for hemoglobinopathies and complications of transplant including resource utilization (hospital readmissions) and endothelial dysfunction.
Prof. Dr. Matthew D. Hall
He is also the Radiation Oncology Residency Program Director at HWCOM.
He has extensive training and experience in the two forms of radiation therapy: standard photon therapy and proton therapy.
His clinical specialty and research focus on innovative ways to treat cancer with radiation therapy while minimizing long-term side effects .
Prof. Dr. Mahmoud Hammad
He received master degree in pediatric oncology in 2008 and doctorate degree in 2013 from NCI, Cairo University.
He had joined Freiburg University, Germany as a transplant fellow from 2014-2015.
He received a master degree in advanced oncology from Ulm University, Germany in 2018.
He is working in the field of pediatric stem
cell transplantation since 2009.
I am interested in bone marrow failure
Syndromes, juvenile myelomonocytic leukemia study and acute myeloid leukemia,
myelodysplastic syndrome and chronic myeloid leukemia study.
Dr. Hammad is a member of the EM-BMT, African-BMT and SIOP groups.
He is the founder of an international education activity “Transplant in Pediatric Hematology Oncology” and Egyptian Pediatric Hematology Oncology Society (EPHOS).
Prof. Dr. Moatasem Elayadi
Dr. El-Ayadi attained his medical degree in 2003 from Kasr El-Ainy School of Medicine, Cairo University, then he completed his fellowship of pediatric hematology oncology at the National Cancer Institute, Cairo University in 2010. After obtaining his Medical Doctorate degree in 2014, he spent a one-year post-doctoral clinical research fellowship of pediatric neuro-oncology at University Hospital of Geneva, CANSEARCH Research Laboratory, Faculty of Medicine, Geneva, Switzerland. Following his return to Egypt and until present, he’s been working as a consultant of pediatric oncology and acting as the PI of the RB study team and co-PI of the neuro-oncology team, at the Children Cancer Hospital of Egypt-57357. Dr. El-Ayadi is a member of several international and national organizations and he is currently a board member of the African SIOP and chairs the membership committee, he is also a member of the SIOP Advocacy Committee and a board member of the EPHOS and African Pediatric Neuro-Oncology Society (APNOS).
Prof. Dr. Michela Casanova
She deals with welfare activities and clinical research in particular with regard to the development of new drugs, soft tissue sarcomas, tumors liver and carcinomas of the nasopharynx.
At international level, she is a member of the Clinical Trial Committee of ITCC (Innovative Therapies for Children with Cancer), of the SIOPEL group (Childhood Liver Tumors Strategy Group) and EpSSG (European pediatric Soft tissue Sarcoma Group – Phase I-II Management Trial Committee).
Member of the working groups of the AIEOP (Italian Association of Pediatric Hematology Oncology) of clinical pharmacology and pharmacosurveillance, rare tumors and bone sarcomas.
Principal Investigator and sub-investigator in numerous clinical protocols sponsored in collaboration with various pharmaceutical companies.
Author and co-author of over 100 papers published in international journals.
Prof. Dr. Miguela Caniza
Her passion is to improve the standards of prevention and care of infections in children globally by building the clinical workforce and institutional processes for best care.
To effectively impact multiple global sites, she builds and sustains networks and working groups of clinicians with expertise in infection care and prevention.
Dr. Caniza uses education, training and continuous mentoring as to improve the ability of local institutional experts and leaders to prevent and manage infections.
In 2012 she received the “HERO” award from the Association of Professionals in Infection Control (APIC) of America for her work to improve capacity of preventionists of infections throughout Latin America. In 2020, her collaboration in education with the Memphis APIC obtained an award from the APIC, Chapter Excellence Award in Education, Communication, and Information Resources.
She continues collaborating with colleagues and organizations worldwide in infection care and prevention and writes extensively in areas of expertise.
Prof. Dr. Mohammed Fateen
He is Double specialized medical doctor in pathology and clinical hematology/hemato-oncology, received four post-graduate degrees with research and teaching interests. Dr Fateen is the Founding Director and Moderator of RBMN/Clinilab research techniques course. He is also Founder & Managing Director of the Regenerative and Bionic Medicine Network (RBMN) of Egypt. He is the Training program in Regenerative Medicine (TPRM) Course Moderator
Prof. Dr. Nabil Ahmed
A physician-scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve therapy for brain tumors.
Aligning with his primary interest is studying the role of T cells in creating a tumor niche and studying T cell migration to distant tumor sites in the brain.
Prof. Dr. Nancy Bolous
For her first role, Nancy teaches the Health Economics course in the Global Child Health Master’s Program and for her second role, she conducts research focused on costing and cost-effectiveness analysis of medical interventions in hematology and oncology.
Nancy’s research projects span several geographic regions in which she collaborates with multiple stakeholders including the World Health Organization, local institutions and governmental bodies.
She joined St. Jude from Cairo, Egypt, where she worked as a project manager on various health care projects on a national and international scale.
Prof. Dr. Nesrine Radwan
She graduated from faculty of Medicine, Ain Shams University and finished MD and PhD in Pediatrics.
She contributed in different research work in multiple areas in the field of Immunology.
Dr.Nesrine had a training in PID laboratory and genetic diagnostics in GOSH, London, UK.
She works as an Immunology Consultant in Children Cancer Hospital-57357 since November 2018 with special interest in the link between PID and cancer predisposition.She is Being interested in human development and assessment center, Dr. Nesrine works as a part time assessor since May 2009.
Prof. Dr. Ramy K. Aziz
Ramy K. Aziz has been working as a professor and chair of the Department
of Microbiology and Immunology at the Faculty of Pharmacy-Cairo University.
He earned his PhD in microbiology and immunology from the University of Tennessee
Health Science Center, USA in 2005, and, since then performed postdoctoral
research at leading institutions including the University of Chicago, San Diego State University, and the University of California San Diego, in which he was a visiting scientist. His research interests span molecular epidemiology, immunogenetics, systems biology of microbial pathogens, evolution and emergence microbial pathogenesis, the human microbiome and pharmacomicrobiomics.
His scientific publications include a book, 7 book sections, 87 articles in peer-reviewed journals, in addition to blogs and web pages oriented to transformative education and science communication.
Prof. Dr. Richard Aplenc
His research focus is in pediatric acute myeloid leukemia (AML) with ongoing clinical epidemiology and translational research projects.
Dr. Aplenc’s current clinical epidemiology research focuses on chemotherapy associated cardiac toxicity and disparities in treatment outcomes for children with AML.
From a translational research standpoint, he lead efforts to identify genetic predictors of anthracycline associated cardiac toxicity and to characterize the AML blast cell surfaceome to identify novel therapeutic targets for pediatric AML.
From a clinic trial perspective, he co-Chair the Pediatric Blood and Marrow Transplant Consortium trial for an anti-CD33 chimeric antigen receptor (CAR) and is also the PI of a local anti-CD123 CAR trial.
In addition, he serves as the Vice-Chair of the Children’s Oncology Group AML Strategy Committee.
Prof. Dr. Ranin Soliman
Ranin is a clinical epidemiologist and researcher in childhood cancer at the Children’s Cancer Hospital Egypt (CCHE57357)
She is also the head of the Health Economics and Value unit at CCHE.
Ranin has extensive professional and research experience in health economics, health informatics, healthcare quality, and is developing her skills in evidence-based healthcare.
Prof. Dr. Reham Abdelaziz Khedr
Senior consultant of Pediatric Hematology/Oncology at Children’s cancer Hospital Egypt 57357
Dr Khedr is a member in the Leukemia /Lymphoma Board at CCHE57357.
She is also a member in the Infectious Diseases team where she is managing infectious complications in patients with cancer.
Her research interest and publications includes but are not limited to Hodgkin Lymphoma and infectious complications in patients with cancer.
Dr. Khedr is an active member in a number of international societies; ASH, ASPHO, EHA, SIOP, ESCMID, ICHS, PIDS and IDSA.
Prof. Dr. Safaa Meshaal
Since then, supervised more than 20 master and MD theses in immunology. Authored and co-authored 33 international publications. Headed the immunology unit at Cairo University Specialized pediatric hospital lab since 2011.
Started the PID diagnostic unit in Cairo University Specialized pediatric hospital in collaboration with Dr. Aisha Elmarsafy in 2011.
Awarded with Dr Ekram Abdelsalam Award in genetics in 2018 and with Dr Mohamed Fakhry award in pediatric research in 2019.
Prof. Dr. Sameh Saad Ali
Ali, a formally trained physical chemist, started to take interest in free radical biology and medicine in 2003 while exploring the extraordinary antioxidant properties of fullerenes in vitro and in vivo. The elegance and complexity of the mitochondrion fascinated Ali that he made a career shift to study the critical roles of mitochondria in aging and diseases.
During his work in the departments of medicine and anesthesiology at the University of California, Ali contributed to many projects in the field of mitochondria function and free radical biology and medicine. His work produced over 50 highly cited articles in high-impact journals including Science, Proceedings of the National Academy of Sciences, Aging Cell, Antioxidant & Redox Signaling, The FASEB Journal, The Journal of Neuroscience, and Free Radical Biology & Medicine.
Prof. Dr. Sajad Khazal
He serves as the program director of pediatric stem cell transplantation and cellular therapy clinical fellowship program.
His areas of research interests include hematopoietic stem cell transplantation and cellular therapy for hematologic malignancies, post-transplant complications including endotheliopathies, and post-transplant maintenance strategies.
Prof. Dr. Shady Fadel
He graduated in 1999 from the medical school at the University of Alexandria
Following graduation he trained and practiced in Alexandria University till 2009
He was assisstant lecturer at the Unit of Peadiatric oncology, Alexandria School of medicine during the period of 2006/2008.
He then moved to the Switzerland where he was Clinical fellow of Peadiatric oncology at the university hospital of Vaud-Lausanne CHUV (2008-2009) .
In 2009 he joined the team of Peadiatric bone marrow Transplant at centre leon Berard, Lyon France.
In 2011 he returned to Alexandria University in Egypt to develop and head a multidisciplinary paediatric oncology program (Alex-POB).
In 2012 Dr.Fadel founded and became CEO of Alexandria Peadiatric Oncology Charity (APOC).
In 2018 he was appointed as General manger of Borg el Arab Children cancer hospital, Alexandria University.
He is author or co-author of 46 peer-reviewed manuscripts in the field of Peadiatric oncology.
His main research interest is Peadiatric Neuroncology and Retinoblastoma.
Prof. Dr. Sherine sadek
Her MD thesis was about “Studying the effect Of Chemo-reduction and focal therapy For Group D Retinoblastoma”.
She has been consulting for the Department of Ocular Oncology at 57357 Children Cancer Hospital since 2015.
Moreover, Dr. Sadek is a consultant of paediatric ophthalmology at the International Eye Hospitals and ROP screening and management at the Legislation Association Hospitals for Premature Infants & Newborns.
She has more than 13 international and local publications.
Dr. Sadek is a member of multiple societies as the Egyptian Association of Paediatric Ophthalmology and Strabismus (EAPOS), the Egyptian Ophthalmological Society (EOS), and American Academy of Ophthalmology (AAO).
Prof. Dr. Valeria Fiaccadori
After completing a fellowship in clinical research at EORTC headquarters in Brussels, she joined the Teenage and Young Adult Unit at UCLH as a clinical fellow in 2015.
Between 2017 and 2020 she undertook a PhD project within the CAR-T cell research group at UCL Cancer Institute.
She joined the team as a consultant haematologist for the Children and Young People’s Cancer Service in February 2021. Her main areas of interest are Hodgkin and non Hodgkin lymphoma, bone marrow transplant and CAR T cells therapy.
Prof. Dr. Youssef Madney
Consultant of Pediatric Hematology and Oncology at the Children’s Cancer Hospital Egypt 57357.
Dr. Madney is a member of the Egyptian Society of Pediatric Oncology, Egyptian Medical Society, Egyptian Medical Syndicate, Egyptian Group of Pediatric Oncology, the Pediatric Oncology East and Mediterranean group, European Society of Clinical Microbiology and Infectious Disease, Society of International Pediatric Oncology, and European Hematology Association.
